A Study LY2228820 for Recurrent Ovarian Cancer

Inclusion Criteria:

Have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer
Have been treated one time with a platinum-based chemotherapy and your disease has come back at least six months after you completed treatment
Are able to swallow tablets
Have given written informed consent prior to any study procedures
Have adequate blood counts, hepatic and renal function
Have performance status equal to or less than 2 on Eastern Cooperative Oncology Group (ECOG) scale
Have negative pregnancy test, and if participant is of child bearing potential must use birth control while on study and for three months after stopping study drug

Exclusion Criteria:

Have been previously treated with Gemcitabine for ovarian, fallopian tube or primary peritoneal cancer
Are currently enrolled or discontinued less than 14 days from another clinical trial
Have a history of inflammatory bowel disease (Crohn's disease or ulcerative colitis)
Have taken certain medications or had grapefruit juice within 7 days of initial dose of study drug, as levels of the study drug may be affected.
Must not be pregnant or breastfeeding.
Have malignancy or metastasis of the central nervous system
Have borderline malignancy